UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020

The breast journal, 2020-01, Vol.26 (1), p.69-80

2020

Volltextzugriff (PDF)

Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology

Clinical breast cancer, 2018-04, Vol.18 (2), p.e187-e195

2018

Volltextzugriff (PDF)

Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies

European journal of cancer (1990), 2011-01, Vol.47 (1), p.74-83

2011

Volltextzugriff (PDF)

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.689-699

2021

Volltextzugriff (PDF)

Integrating PARP inhibitors into the management of breast cancer: where are we?

Chinese Clinical Oncology, 2021-10, Vol.10 (5), p.50-50

2021

Volltextzugriff (PDF)

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

Breast (Edinburgh), 2022-08, Vol.64, p.151-158

2022

Volltextzugriff (PDF)

Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

Biomarkers, 2022-11, Vol.27 (8), p.764-772

2022

Volltextzugriff (PDF)

Treatment of HER2‐positive early breast cancer: How to best balance efficacy and toxicity?

The breast journal, 2018-07, Vol.24 (4), p.459-461

2018

Volltextzugriff (PDF)

Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial

Journal of chemotherapy (Florence), 2024-05, p.1-9

2024

Volltextzugriff (PDF)

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Journal of clinical oncology, 2024-08, Vol.42 (23), p.2812-2821

2024

Volltextzugriff (PDF)

Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations

Cancer, 2024-10, Vol.130 (19), p.3251-3271

2024

Volltextzugriff (PDF)

Tailoring neo/adjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations

Cancer, 2024-07

2024

Volltextzugriff (PDF)

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

The oncologist (Dayton, Ohio), 2018-10, Vol.23 (10), p.1137-1143

2018

Volltextzugriff (PDF)

Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis

JCO global oncology, 2023-03, Vol.9 (9), p.e2200387

2023

Volltextzugriff (PDF)

Understanding the benefits and challenges of first‐line cyclin‐dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women

The breast journal, 2020-04, Vol.26 (4), p.630-642

2020

Volltextzugriff (PDF)

The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer

Oncology and therapy, 2023-12, Vol.11 (4), p.445-459

2023

Volltextzugriff (PDF)

Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

Breast cancer research and treatment, 2022, Vol.191 (1), p.223-224

2022

Volltextzugriff (PDF)

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

BMC cancer, 2012-09, Vol.12 (1), p.423-423, Article 423

2012

Volltextzugriff (PDF)

Breast cancer in Egypt, China and Chinese: statistics and beyond

Journal of thoracic disease, 2014-07, Vol.6 (7), p.864-866

2014

Volltextzugriff (PDF)

Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis

Current problems in cancer, 2020-12, Vol.44 (6), p.100592-100592, Article 100592

2020

Volltextzugriff (PDF)

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

Cancers, 2021-05, Vol.13 (9), p.2262

2021

Volltextzugriff (PDF)

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231212182-17588359231212182

2023

Volltextzugriff (PDF)

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

Journal of breast cancer, 2019-03, Vol.22 (1), p.141

2019

Volltextzugriff (PDF)

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

Translational oncology, 2016-04, Vol.9 (2), p.114-123

2016

Volltextzugriff (PDF)

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions

Future oncology (London, England), 2012-02, Vol.8 (2), p.135-144

2012

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(62)
Oncology
(45)
Humans
(32)
Breast Cancer
(23)
Female
(20)
Male
(11)
Egypt
(10)
Middle Aged
(10)
Obstetrics & Gynecology
(9)
Breast Neoplasms - Pathology
(8)
Cancer
(8)
Medicine
(8)
Adult
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Biological And Medical Sciences
(7)
Care And Treatment
(7)
Chemotherapy
(7)
Hematology, Oncology And Palliative Medicine
(7)
Medicine & Public Health
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020

Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology

Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies

Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

Integrating PARP inhibitors into the management of breast cancer: where are we?

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

Treatment of HER2‐positive early breast cancer: How to best balance efficacy and toxicity?

Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations

Tailoring neo/adjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

Clinicopathologic Features of Breast Cancer in Egypt-Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis

Understanding the benefits and challenges of first‐line cyclin‐dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women

The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer

Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population

A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

Breast cancer in Egypt, China and Chinese: statistics and beyond

Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort

Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions

Suchergebnisse filtern